ABIVAX ANNOUNCES SUCCESSFUL OVERSUBSCRIBED EUR 49.2M CROSS-OVER FINANCING WITH TOP-TIER US AND EUROPEAN BIOTECH INVESTORS

Written by Kai Schmitz on 2nd September 2022. Posted in Client News.

• Previous
• Next